Anupam Rasayan India Limited Overview
Anupam Rasayan is a Surat-headquartered custom synthesis and manufacturing (CSM) and specialty chemicals company that has spent the past five years converting itself from a predominantly agrochemical-intermediates supplier into a multi-chemistry, multi-geography CDMO platform. Its historic core is multi-step synthesis for global innovator agrochemical, personal-care and pharmaceutical companies from six plants in Gujarat (~30,000 MT installed capacity). Through three acquisitions it has added backward integration into fluorine (Tanfac Industries, 2022), a US manufacturing base serving electronics, resins and defence-adjacent performance materials (Jayhawk Fine Chemicals, Kansas, closed February 2026), and forward integration into finished pharmaceutical dosage forms (Bliss GVS Pharma, control acquired September 2026). Management frames the combined group as a ~INR 4,000 Cr pro forma revenue platform. The investment case rests on contracted LOI/order-book visibility, fluorination and flow-chemistry know-how, and operating leverage on under-utilised acquired assets; the principal offsets are rising leverage, margin dilution, and a rich valuation.
Company's own description. In its exchange press releases (e.g., FY2026 results release of 23 May 2026 and Q1 FY27 release of 14 August 2026) the company describes itself as one of the leading Indian companies engaged in custom synthesis and manufacturing of specialty chemicals, offering multi-step synthesis and complex chemical reaction technologies to a diverse base of Indian and global customers, operating two business verticals: (i) life-science-related specialty chemicals (agrochemicals, personal care, pharmaceuticals) and (ii) other specialty chemicals / performance materials (specialty pigments and dyes, polymer additives, electronics, EV and battery chemicals, polymers). Management's stated ambition, reiterated in Q4 FY26 and Q1 FY27 commentary, is to build a "globally integrated specialty chemicals and CDMO platform."
Business model. The core model is contract/custom manufacturing: an innovator customer (typically a multinational) transfers or co-develops a molecule (usually an advanced intermediate or active ingredient precursor), Anupam develops and scales the process, and supplies under multi-year purchase agreements or letters of intent (LOIs). Revenue is overwhelmingly product sales (manufactured chemicals sold per kilogram/tonne); there is no material subscription or licensing revenue. Following the Bliss GVS acquisition, a branded-generic formulations business (150+ brands, per acquisition announcement) adds a new revenue type — branded product sales into emerging markets (Africa, Asia, Latin America) and regulated-market supply.
Revenue-model mix (independent characterisation).
Pro forma split per the company's Bliss completion release (29 Sep 2026): standalone INR 1,676 Cr, Tanfac INR 711 Cr, Jayhawk INR 722 Cr, Bliss GVS INR 927 Cr (total ≈ INR 4,036 Cr).
Value-chain position. Anupam sits in the "N-1 / N-2" position: it manufactures advanced intermediates one or two steps before the final active ingredient, plus some actives. Tanfac moves it upstream into basic fluorine (hydrofluoric acid, potassium fluoride, aluminium fluoride), securing key fluorination inputs. Bliss moves it downstream into finished dosage forms (suppositories, pessaries, tablets, capsules, injectables). Jayhawk adds a US-located N-1 capability for epoxy/polyimide/hybrid-resin additives, electronics and semiconductor materials.
Customer types. Global innovator agrochemical companies; Japanese, Korean and European chemical and electronics multinationals (polymer intermediates, liquid-crystal intermediates, engineering fluids, semiconductor/data-centre materials); personal-care ingredient majors; pharmaceutical innovators and generics (KSMs, intermediates, and via Bliss, distributors and governments in emerging markets); battery developers (BasqueVolt LOI). In April 2024 the company stated it served over 73 domestic and international customers including 29 multinationals (company press release, 2 April 2024). Named customers are generally not disclosed due to confidentiality; LOI counterparties are typically described only as "a leading Japanese multinational" etc.
End-markets. Crop protection (55% of standalone FY26 revenue, down from 76% in FY22); pharmaceuticals; personal care; performance materials (polymers/high-performance thermoplastics for aerospace, semiconductor process materials, electronics, liquid crystals, engineering fluids, refrigerants via Tanfac's HFC-32 project); EV / solid-state battery materials; defence and aviation (Jayhawk).
Strategy
Stated strategy (paraphrased themes from FY2026 annual report, results releases and calls).
-
Build a globally integrated specialty chemicals and CDMO platform spanning KSMs to finished dosage forms.
-
Diversify away from agrochemicals (76% of standalone revenue in FY2022 → 55% in FY2026) towards pharma, performance materials, electronics, semiconductors, EV/battery and aerospace/defence chemistries.
-
Deepen fluorination chemistry, anchored by Tanfac backward integration and the ETFA flow platform.
-
Win long-term, contract-backed volume via LOIs/MPAs with Japanese, Korean and European multinationals; LOI/contract pipeline totals ~INR 17,496 Cr (Q1 FY27 presentation) and order book stood at INR 14,646 Cr at FY2026.
-
Use acquisitions of under-utilised assets (Jayhawk <10% land use; Bliss ~30% capacity utilisation) to create operating leverage and cross-selling.
-
Fund growth with structured minority equity and debt to limit parent-level equity dilution.
Initiatives in last 24 months.
Medium-term targets / guidance.
No margin, ROCE or leverage targets were verifiably published.
Products & Services
As a CSM business, Anupam does not publish a molecule-level catalogue; customer confidentiality covers most products. The company reports 125+ commercialised products after adding three in Q1 FY27 (Q1 FY27 investor presentation) and a development pipeline of 90+ molecules (FY2026 presentation, per FilingReader). Below is the most granular public catalogue available.
ARIL standalone — Life sciences
| Product line | Description / capabilities | Target customer | Year / status | Pricing |
|---|---|---|---|---|
| Agrochemical advanced intermediates & actives | Multi-step synthesis of intermediates for insecticides, herbicides, fungicides; capabilities across fluorination, nitration, chlorination, hydrogenation and other complex reactions (company "complex chemical reactions" positioning) | Global innovator crop-protection MNCs | Core since 1984; 55% of FY26 standalone revenue | Long-term contract / LOI pricing; not disclosed |
| Pharmaceutical intermediates & KSMs | Key starting materials and intermediates; fluorinated building blocks | Pharma innovators / generics; now captive into Bliss formulations | Growing; management expects pharma to outgrow agro | — |
| Personal-care ingredients | Specialty molecules for personal care (e.g., cosmetic actives / UV-related chemistries — specific molecules not disclosed) | Personal-care ingredient majors | Established vertical | — |
ARIL standalone — Performance materials / other specialty chemicals
| Product / programme | Description | Counterparty | Date | Contract value |
|---|---|---|---|---|
| Polymer & liquid-crystal intermediates (3 molecules) | Advanced intermediates for highly specialised polymers and liquid crystals; Anupam exclusive supplier out of India | Leading Japanese multinational | Early 2023 | ~$182m (INR 1,500 Cr) over 7 years |
| New-age polymer intermediate | Intermediate for thermoplastic polymers used in aerospace structural materials, semiconductor process materials, E&E devices, industrial machinery; fully backward-integrated | Leading Japanese chemical company | 25 Dec 2023 (supply from CY2024) | $61m (INR 507 Cr) over 9 years |
| Engineering-fluids molecules | Molecules for engineering fluids | Large Japanese multinational | 2 Apr 2024 | ~$90m (INR 743 Cr) over 7 years |
| Semiconductor / data-centre niche molecules | Multiple niche molecules under a long-term Master Purchase Agreement | Japan-based multinational conglomerate | 12 Jun 2025 | — |
| Korean MNC programme | 10-year LOI (molecule not disclosed) | Korean multinational | — | INR 922 Cr over 10 years (IIFL headline) |
| Battery specialty chemical | Specialty chemical for solid-state lithium-metal batteries; subject to product development | BASQUEVOLT, S.A. (Miñano, Spain) | 15 Jul 2026 | Up to $300m cumulative over up to 10 years (non-binding) |
| Specialty pigments & dyes, polymer additives | Legacy "other specialty chemicals" lines | Industrial customers | Established | — |
Flagship technology product — ETFA
| Attribute | Detail |
|---|---|
| Product | Ethyl trifluoroacetate (ETFA), a fluorinated building block and reagent used to make organic fluorine compounds across pharma, agro and performance materials |
| Technology | Proprietary "process-by-design" continuous flow chemistry platform; company claims world-first commercial-scale flow production |
| Launch | Commercialised June 2026 (press release 11 Jun 2026) |
| Addressable market | ~$500–600m globally (company estimate) |
| Claimed advantages | Safety, reproducibility, scalability, efficiency, lower environmental footprint vs batch |
Tanfac Industries (fluorochemicals & inorganics, Cuddalore)
| Product | Use |
|---|---|
| Anhydrous / aqueous hydrofluoric acid | Feedstock for fluorination; refrigerants; captive to ARIL |
| Aluminium fluoride | Aluminium smelting flux |
| Sodium silicofluoride | Water fluoridation, glass, enamels |
| Potassium fluoride | Fluorinating agent (key ARIL input — backward integration rationale) |
| Sulphuric acid and oleum | Industrial acids; captive and merchant |
| HFC-32 (R-32 refrigerant) — project | Commercialisation targeted Q3 FY27 (management, Q1 FY27 call) |
| Fluorine derivatives for agro, pharma, polymers | Value-added derivatives planned since 2022 acquisition |
Tanfac was incorporated 20 December 1972, began commercial production March 1985, and reported FY2026 turnover of INR 711.1 Cr and net worth of INR 373.2 Cr (ARIL Reg. 30 disclosure, 7 Sep 2026). Its single 60-acre site adjoins Cuddalore Port.
Jayhawk Fine Chemicals (USA)
| Product line | Description |
|---|---|
| Epoxy, polyimide and hybrid-resin additives / curing agents | High-performance resins for electronics, energy and infrastructure (CABB description) |
| Advanced intermediates and active ingredients | Custom manufacturing for regulated-market customers |
| High-performance materials | Semiconductor, electronics, aviation, defence-adjacent applications (ARIL release) |
Jayhawk was founded in 1941; it reported ~$78m revenue and ~$15m EBITDA in calendar 2024 (CABB/ARIL), and has an ~800-acre site with below 10% land utilisation (management, Q1 FY27).
Bliss GVS Pharma (formulations, from 28 Sep 2026)
| Product line | Description |
|---|---|
| Suppositories & pessaries | Core franchise; described as India's first EU-GMP-certified suppository manufacturer; women's-health strength |
| Tablets, capsules, injectables | Finished dosage forms |
| Therapeutic coverage | 150+ brands across anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic, cardiovascular |
| Capacity | Plants running at ~30% utilisation; management targets 60–70% in 2–3 years |
Financial Narrative
Margins (computed from table 6.1)
Revenue CAGR FY2022–FY2026: 21.8% (INR 10,738M → INR 23,655M). FY2023–FY2026 CAGR: 13.9%.
Commentary. The five-year record has three phases. FY2022–FY2023 expansion: post-IPO capacity additions and the Tanfac consolidation drove revenue up 49% in FY2023, but gross margin fell ten points as Tanfac's lower-value inorganic fluorides entered the mix. FY2024–FY2025 agro destocking: global crop-protection channel destocking cut revenue in two consecutive years (−7.9% and −2.6%); Q2 FY25 revenue fell 25% YoY. Operating margins held around 20–21% but rising interest (INR 489M → INR 1,014M) compressed net income to INR 933M in FY2025. FY2026 inflection: revenue jumped 65% on agro recovery, new molecule commercialisation (3 new products), full-year contribution of electronics/polymer LOIs and one month of Jayhawk. However, gross margin fell to 44% (consolidated gross margin declined from 61% to 43% between 9M FY25 and 9M FY26 per company data) and EBITDA margin from 28% to 23%, reflecting mix (lower-margin volume products, Tanfac, Jayhawk at ~19% EBITDA margin) and raw-material pass-through. Q4 FY26 EBITDA margin fell to 22% from 30% YoY. Profit growth (+39% consolidated PAT) lagged revenue growth, and interest cost rose a further 47% to INR 1,487M.
Quarterly trajectory: notes and sources
Notes: Q2 FY26 operating revenue and Q3 FY26 EBITDA/PAT are derived by subtraction from reported 9M and FY totals (9M FY26 EBITDA INR 4,024M; 9M PAT INR 1,660M; FY26 totals), and reconcile to reported annual figures within rounding. Q2 FY26 revenue was reported as INR 731.3 Cr (+148% YoY) with EBITDA margin of 18.6% (Motilal Oswal). Q1 FY27 EBITDA excluding other income was ~INR 1,620M (24.8% margin) versus 26.2% including other income — both figures appear in coverage; the difference is other income. Q1 FY27 PAT attributable to owners was INR 386.4M; depreciation rose to INR 561M from INR 307M, driven by Jayhawk and new assets.
Balance sheet
Goodwill & intangibles: not separately verified; FY2026 total assets rose by INR 27.4bn, largely from the Jayhawk consolidation (~$150m purchase price), implying material goodwill/intangible recognition — check FY2026 annual report Note on business combinations. FY2026 classification shows almost all debt as current (INR 13,038M current portion), which likely reflects working-capital facilities and acquisition bridge borrowings reclassified; refinancing is a monitorable.
Important off-balance-sheet-style feature: Both the Jayhawk ($109m Class B non-voting shares in Doriath, funded largely by an Oaktree Capital affiliate, Altis XII Pte) and Bliss (non-controlling, non-voting equity instruments for the portion above a INR 300 Cr term loan) were funded with structured minority equity. These instruments sit in non-controlling interest rather than debt, so reported debt/equity understates economic leverage; their return terms (preferred return, exit/put rights) are not publicly detailed.
Cash flow
FY2026 OCF was the company's highest ever (FY2026 release). S&P Global data show negative free cash flow per share every year FY2022–FY2026 except FY2023 (INR −31.73, 6.86, −60.66, −40.05, −19.59), i.e., the business has been a persistent consumer of cash due to capex and working capital. No buybacks have been authorised.
Ratios (computed)
ROIC and cash conversion cycle: not publicly disclosed on a consistent basis; standalone inventory rose from INR 863 Cr (FY2022) to INR 1,355 Cr (FY2025) (IIFL data), indicating a structurally long cash cycle typical of CSM (campaign manufacturing and safety stocks for MNC customers).
Trend synthesis. Returns on equity have been in mid-single digits for three years — well below cost of equity — because equity was raised ahead of earnings (IPO 2021, FY2023 raise, 2023–25 preferential issue/warrants) and assets have grown faster than profits. Interest coverage has deteriorated steadily from 10x to 2.6x. The FY2026 improvement in net debt/EBITDA (to 2.8x) is flattered by the reclassification of acquisition funding into minority equity. The equity story depends on Jayhawk/Bliss utilisation gains lifting asset turns from ~0.3x.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Relationship | Function |
|---|---|---|---|
Anupam Rasayan India Ltd | India | Parent | CSM / specialty chemicals, six Gujarat plants |
Tanfac Industries Ltd | India (listed, BSE 506854) | Subsidiary (joint sector company with TIDCO; ARIL co-promoter with control) | Fluorochemicals and inorganics, Cuddalore |
Anupam Japan GK | Japan | Wholly owned subsidiary | Business development / sales, Japan |
Anupam Europe AG | — | Wholly owned subsidiary | Business development, Europe |
Anupam USA, LLC | USA | Wholly owned subsidiary | US sales |
Anupam General Trading FZE | UAE (JAFZA) | Wholly owned subsidiary | Trading, storage, export distribution |
Doriath S.à r.l. | Luxembourg | Subsidiary (ARIL holds voting control; Class B non-voting shares held by Oaktree affiliate) | Acquisition vehicle for Jayhawk |
Jayhawk Fine Chemicals Corporation | USA (Galena, Kansas) | 100% held by Doriath | Performance materials, electronics, resin additives |
Mates Visa Consultancy Pvt Ltd | India | Wholly owned SPV (acquired 16 Jul 2026 for INR 0.01M) | Acquisition vehicle / PAC for Bliss GVS |
Bliss GVS Pharma Ltd | India (listed) | Subsidiary from 28 Sep 2026 (ARIL + PAC 50.07%) | Finished dosage formulations |
Business Verticals
| Vertical (% of standalone revenue) | FY2022 | FY2026 |
|---|---|---|
Agrochemicals (%) | 76 | 55 |
Vertical (% of standalone FY2026 revenue) | Source A: earnings-call summary (GuruFocus, 25 May 2026) | Source B: investor presentation summary (Multibagg, 23 May 2026) |
Agrochemicals | 55 | 55 |
Pharmaceuticals | 20 | 7 |
Performance materials | 18 | 20 |
Personal care | 7 | 18 |
Business Verticals (FY2026)
| Vertical (INR Mn, derived) | FY2026 |
|---|---|
Agrochemicals | 9,216 |
Pharmaceuticals | 3,351 |
Performance materials | 3,016 |
Personal care | 1,173 |
Group Entities — ARIL standalone
| Entity (INR Cr, pro forma annual) | Pro forma |
|---|---|
ARIL standalone | 1,676 |
Bliss GVS Pharma | 927 |
Jayhawk Fine Chemicals | 722 |
Tanfac Industries | 711 |
Total | 4,036 |
Results by Segment
| Metric | FY2025 | FY2026 |
|---|---|---|
Standalone operating revenue (INR Mn) | 8,959 | 16,756 |
Standalone total income (INR Mn) | 9,092 | 16,955 |
Standalone PAT (INR Mn) | 727 | 1,614 |
Consolidated operating revenue (INR Mn) | 14,370 | 23,655 |
Consolidated PAT incl. minorities (INR Mn) | 1,600 | 2,222 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating revenue (INR Mn) | 10,738 | 16,019 | 14,751 | 14,370 | 23,655 |
Revenue growth YoY (%) | 31.6 | 49.2 | -7.9 | -2.6 | 64.6 |
Cost of revenue (INR Mn) | 3,721 | 7,166 | 6,290 | 6,203 | 13,233 |
Gross profit (INR Mn) | 7,016 | 8,853 | 8,461 | 8,166 | 10,422 |
SG&A (INR Mn) | 486 | 690 | 754 | 744 | 866 |
Operating income (INR Mn) | 2,448 | 3,605 | 3,016 | 2,994 | 3,849 |
Interest expense (INR Mn) | 242 | 489 | 793 | 1,014 | 1,487 |
Net income attributable to owners (INR Mn) | 1,522 | 1,808 | 1,286 | 933 | 1,701 |
Dividend per share (INR) | 1.50 | 2.50 | 1.25 | 0.75 | 1.50 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2025–FY2026)
| Metric (company-reported, INR Mn) | FY2025 | FY2026 |
|---|---|---|
Total income incl. other income (INR Mn) | 14,485 | 23,836 |
EBITDA incl. other income (INR Mn) | 4,123 | 5,430 |
EBITDA margin (%) | 28.5 | 22.8 |
Consolidated PAT incl. NCI (INR Mn) | 1,600 | 2,222 |
PAT margin (%) | 11.0 | 9.3 |
Basic & diluted EPS (INR) | — | 15.09 |
Operating cash flow (INR Mn) | — | 3,343 |
Capex (INR Mn) | — | 3,150 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 65.3 | 55.3 | 57.4 | 56.8 | 44.1 |
Operating margin (%) | 22.8 | 22.5 | 20.4 | 20.8 | 16.3 |
Net margin, owners (%) | 14.2 | 11.3 | 8.7 | 6.5 | 7.2 |
Income Statement
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Operating revenue (INR Mn) | 4,858 | 7,315 | 5,124 | 6,358 | 6,550 |
EBITDA incl. other income (INR Mn) | 1,292 | 1,357 | 1,375 | 1,407 | 1,749 |
Consolidated PAT incl. NCI (INR Mn) | 485 | 440 | 735 | 560 | 512 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 28,905 | 37,779 | 46,017 | 52,689 | 80,126 |
Cash & equivalents (INR Mn) | 423 | 1,878 | 2,498 | 1,130 | 3,936 |
Cash & short-term investments (INR Mn) | 454 | 6,245 | 3,498 | 1,282 | 4,106 |
Short-term debt (INR Mn) | 2,081 | 2,357 | 6,982 | 10,290 | 0 |
Current portion of LT debt (INR Mn) | 933 | 1,968 | 1,234 | 1,176 | 13,038 |
Long-term debt (INR Mn) | 4,945 | 3,550 | 1,971 | 1,712 | 5,108 |
Total debt (INR Mn) | 8,362 | 8,217 | 10,691 | 14,261 | 19,129 |
Net debt (INR Mn) | 7,908 | 1,972 | 7,192 | 12,978 | 15,023 |
Total common equity (INR Mn) | 17,269 | 23,726 | 27,610 | 28,503 | 33,338 |
Total current assets (INR Mn) | 14,466 | 21,112 | 22,266 | 25,730 | 37,275 |
Total current liabilities (INR Mn) | 5,951 | 8,108 | 13,162 | 18,082 | 26,154 |
Working capital (INR Mn) | 8,515 | 13,004 | 9,104 | 7,648 | 11,121 |
Shares outstanding (M) | 100.25 | 107.46 | 109.79 | 109.93 | 113.73 |
Cash Flow and Per-Share Data
| Metric (INR Mn) | FY2025 | FY2026 |
|---|---|---|
Operating cash flow (INR Mn) | — | 3,343 |
Capex (INR Mn) | — | 3,150 |
Free cash flow, OCF − capex (INR Mn) | — | 193 |
Dividends declared per share (INR) | 0.75 | 1.50 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE, owners NI / closing equity (%) | 8.8 | 7.6 | 4.7 | 3.3 | 5.1 |
ROA, owners NI / total assets (%) | 5.3 | 4.8 | 2.8 | 1.8 | 2.1 |
Current ratio (x) | 2.43 | 2.60 | 1.69 | 1.42 | 1.43 |
Debt / equity (x) | 0.48 | 0.35 | 0.39 | 0.50 | 0.57 |
Interest coverage, EBIT / interest (x) | 10.1 | 7.4 | 3.8 | 3.0 | 2.6 |
Asset turnover (x) | 0.37 | 0.42 | 0.32 | 0.27 | 0.30 |
Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
Net debt / EBITDA (x) | 3.15 | 2.77 |
Geography Metric Details
| Geography metric | Q1FY27 |
|---|---|
Export share of consolidated revenue (%) | 36 |
Share Price & Returns
| Reference point | Price (INR) | Return to ₹1,170.50 (16 Oct 2026) |
|---|---|---|
IPO price (Mar 2021) | 555 | +111% |
~18 Oct 2025 | 1,061.05 | +10.3% |
3-year (as of Sep 2026, Anand Rathi) | — | ~+24.6% |
52-week high / low | 1415.40 / 1047.40 | −17.3% / +11.8% |
Market Valuation
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
Year-end market cap (INR Bn) | 99.00 | 72.84 | 115.22 | 79.39 | 150.15 |
Valuation Multiples
| Multiple | Anupam Rasayan | Source / note |
|---|---|---|
P/E (TTM) | ~81x | IIFL (80.9x), Kotak (81.4x) |
P/E FY2027E | ~41x | MarketScreener consensus |
P/B | ~4.1x | IIFL (book value ₹286.95) |
EV/Sales FY2026 | ~6x (approx.; EV ~INR 147bn / sales INR 23.7bn) | Derived; EV excludes minority-equity instruments |
EV/EBITDA FY2026 | ~36x | Trendlyne (36.2x) |
Specialty-chem peer P/E | ~30x FY28E | Deven Choksey |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 1.50 | 2.50 | 1.25 | 0.75 | 1.50 |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
CRISIL | Long-term bank facilities / NCDs | A+ | Rating Watch with Developing Implications | Placed 4 Jun 2026; continued 31 Aug 2026 |
CRISIL | Short-term facilities | A1 | Watch Developing | Same |
Moody's / S&P / Fitch | — | Not rated | — | — |
Analyst Conclusions
Management guidance (Q1 FY27 call, 14 Aug 2026). FY27 consolidated revenue growth above 30% (organic 20–25% plus 10–15 pp from Jayhawk), excluding Bliss (consolidated from late September 2026, which adds a further increment to H2 FY27). Tanfac HFC-32 commercialisation in Q3 FY27. Bliss utilisation to double over 2–3 years. No explicit margin guidance.
Consensus expectations. FY27E revenue ~INR 34.6bn and FY28E ~INR 45.8bn (Deven Choksey); FY27E P/E ~41x implies roughly doubling EPS from FY2026's ₹15.09.
Bull case.
-
Operating leverage on acquired assets: Jayhawk (<10% site utilisation, ~19–20% EBITDA margin) and Bliss (30% utilisation) can grow with modest capex, lifting asset turns from ~0.30x and ROE from ~5% toward double digits.
-
Contracted pipeline conversion: ~INR 17,500 Cr of LOIs/contracts — about 7x FY2026 revenue — skewed to electronics, polymers and battery materials with higher structural growth than agro.
-
Technology moat in fluorine: integrated HF→KF→ETFA→fluoropolymer intermediates plus first-mover flow chemistry in a $500–600m ETFA market.
Bear case.
-
Earnings quality and leverage: PAT grew 6% in Q1 FY27 on 36% revenue growth; interest coverage is 2.6x; FCF has been negative in four of five years; CRISIL watch persists.
-
Hidden cost of structured equity: Oaktree-funded Class B shares ($109m at Doriath) and Bliss non-voting instruments shift economics to minorities — consolidated PAT of INR 2,222M vs owners' INR 1,701M in FY2026 already shows ~23% leakage.
-
Valuation: ~81x trailing P/E and ~36x EV/EBITDA versus specialty-chem peers at ~30x forward P/E leave little margin for integration slippage or agro relapse.
Catalysts & monitorables (next 12 months).
-
Q2 FY27 results (expected late Oct/Nov 2026; trading window closed 1 Oct) — first full Jayhawk quarter, margin trajectory.
-
First Bliss consolidation (Q3 FY27) and any segment re-definition.
-
CRISIL resolution of Watch Developing.
-
Tanfac HFC-32 start-up (Q3 FY27).
-
ETFA customer qualifications and volumes; additional flow-chemistry molecules.
-
Conversion of BasqueVolt LOI to definitive supply agreement.
-
Promoter pledge levels; disclosure of minority-equity terms.
-
Refinancing of current debt; working-capital release.
-
Q4 FY27 delivery against >30% growth guidance.
Analyst verdict. Anupam Rasayan has executed one of the most aggressive transformations among Indian mid-cap specialty chemical companies. In under five years it has moved from a Gujarat-based, agro-heavy custom synthesiser to a four-pillar group — standalone CSM, Tanfac fluorochemicals, Jayhawk US performance materials and Bliss GVS formulations — with pro forma revenue near INR 4,000 Cr, roughly 1.7x FY2026 reported revenue. The strategic logic is coherent: fluorine integration and flow chemistry provide technical differentiation; Japanese electronics and polymer contracts diversify end-markets; and buying under-utilised assets creates operating leverage that greenfield capex could not deliver as quickly.
The financial evidence, however, has not yet caught up with the narrative. Margins have compressed (EBITDA from 28% to 23% in FY2026), returns on equity remain around 5%, interest coverage has fallen to 2.6x, and free cash flow has been persistently negative. The heavy use of structured minority equity keeps headline leverage manageable but diverts a growing share of profits away from ordinary shareholders and obscures the true cost of capital. CRISIL's continued watch status is a reasonable reflection of that uncertainty.
At ~81x trailing and ~41x forward earnings, the market is already discounting successful integration and pipeline conversion. The next three to four quarters are therefore decisive: investors should look for (i) consolidated EBITDA margins stabilising at or above the mid-20s with Bliss included, (ii) PAT growth converging with revenue growth as depreciation and interest normalise, (iii) clear disclosure of the economics of the Oaktree and Bliss instruments, and (iv) deleveraging or credit-watch resolution. Our synthesis: strategically well-positioned and operationally improving, but priced for execution.
Principal sources: NSE/BSE filings and press releases of Anupam Rasayan India Ltd (FY2025–Q1 FY27); FY2025-26 Integrated Annual Report (submission notice, Sep 2026); CRISIL rating rationales (Mar, Jun, Aug 2026); CABB Group press release (26 Feb 2026); Bliss GVS Pharma SAST disclosures (Sep 2026); S&P Global Market Intelligence data via StockAnalysis.com; Value Research, Upstox, Anand Rathi, IIFL, MarketScreener, Sustainalytics; Deven Choksey Research via DSIJ (Aug 2026); Business Standard, Reuters, Outlook Business, Indian Chemical News, Chemical Weekly, Multibagg, FilingReader, Investywise summaries of filings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / context | Notes |
|---|---|---|---|
Anand Desai | Managing Director | Founder-promoter; leads company since partnership era | Public face of all major transactions |
Mona Desai | Vice-Chairperson & Whole-time Director (title per company materials; verify) | Promoter family | — |
Gopal Agrawal | Chief Executive Officer | Listed as CEO on Q2 FY26 earnings call (Oct 2025) | — |
Amit Khurana | Chief Financial Officer | Listed as CFO on Q2 FY26 call | — |
Ravi Desai | Chief Operating Officer | Promoted from Sales Head; COO effective 14 Aug 2026; remains KMP | — |
Hetvi Vyas | Deputy CFO & KMP | Effective 8 Sep 2026; CA with 9+ years' experience; joined 2023; managed international subsidiaries and post-acquisition integration | Replaced Vishal Thakkar |
Vishal Thakkar | Former Deputy CFO | Resigned effective 23 May 2026 | — |
Shareholding Trend
| Holder category (%) | Jul2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|
Promoters (%) | 59.07 | 59.07 | 59.07 | 59.07 | 59.07 |
FIIs (%) | 7.75 | 7.63 | 7.60 | 6.91 | 7.52 |
Mutual funds (%) | 1.78 | 1.03 | 0.09 | 0.15 | — |
Other DIIs (%) | 0.10 | 0.35 | 0.33 | 0.20 | 0.39 |
Major Shareholders
| Holder | Stake | Category |
|---|---|---|
Kiran Pallavi Investments LLC | ~32.9% | Foreign promoter (MarketsMOJO) |
Anand Desai, Mona Desai and Indian promoter group | ~26% (residual of 59.07%) | Indian promoters |
Foreign portfolio investors (aggregate) | ~7–8% | — |
Mutual funds | <0.5% | Domestic MF ownership has collapsed from 5.91% (Dec 2022) |
Competitive Landscape
Competitors by Segment
| Segment | Named competitors |
|---|---|
Indian CSM / agro intermediates | PI Industries, Navin Fluorine (CDMO), Aarti Industries, Tatva Chintan, Neogen Chemicals |
Fluorochemicals | SRF Ltd, Navin Fluorine International, Gujarat Fluorochemicals |
Specialty / advanced intermediates | Aether Industries, Deepak Nitrite, Clean Science & Technology, Laxmi Organic, Fine Organic Industries |
Global CDMO / fine chemicals | Lonza, Siegfried, CABB Group, Saltigo (Lanxess), WuXi STA |
US performance materials (Jayhawk) | VanDeMark Chemical and others (CB Insights) |
Formulations / suppositories (Bliss) | Not specifically benchmarked; Indian branded-generic exporters to Africa |
Peer Comparison FY2026
| Metric | Anupam Rasayan | Aether Industries | Deepak Nitrite | Aarti Industries | Fine Organic |
|---|---|---|---|---|---|
Market cap (INR Cr) | 13,439 | 22,548 | 20,882 | 17,265 | 15,706 |
Revenue TTM (INR Cr) | 2,535 | 1,224 | 8,575 | 9,013 | 2,472 |
Net profit TTM (INR Cr) | 225 | 235 | 783 | 531 | 442 |
Net margin (%) | 8.79 | 18.79 | 9.08 | 5.88 | 17.20 |



